Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fuji
Accenture
AstraZeneca
Medtronic
Mallinckrodt
Cerilliant
Healthtrust
Farmers Insurance

Generated: May 21, 2018

DrugPatentWatch Database Preview

Eisai Inc Company Profile

« Back to Dashboard

Summary for Eisai Inc
International Patents:550
US Patents:30
Tradenames:13
Ingredients:11
NDAs:17
Drug Master File Entries: 1
Patent Litigation for Eisai Inc: See patent lawsuits for Eisai Inc

Drugs and US Patents for Eisai Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-001 Nov 14, 2008 DISCN Yes No 6,740,669*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Eisai Inc FYCOMPA perampanel SUSPENSION;ORAL 208277-001 Apr 29, 2016 RX Yes Yes 8,772,497 ➤ Try a Free Trial Y ➤ Try a Free Trial
Eisai Inc FYCOMPA perampanel SUSPENSION;ORAL 208277-001 Apr 29, 2016 RX Yes Yes 6,949,571 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-001 Feb 13, 2015 RX Yes No 7,612,208 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Eisai Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc ARICEPT ODT donepezil hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021720-001 Oct 18, 2004 4,895,841 ➤ Try a Free Trial
Eisai Inc ACIPHEX rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 020973-001 May 29, 2002 5,035,899 ➤ Try a Free Trial
Eisai Inc PANRETIN alitretinoin GEL;TOPICAL 020886-001 Feb 2, 1999 5,932,622 ➤ Try a Free Trial
Eisai Inc ARICEPT donepezil hydrochloride TABLET;ORAL 022568-001 Jul 23, 2010 4,895,841 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for EISAI INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Orally Disintegrating Tablets 5 mg and 10 mg ➤ Subscribe 2010-06-30
➤ Subscribe Tablets 23 mg ➤ Subscribe 2013-07-09
➤ Subscribe Tablets 10 mg ➤ Subscribe 2016-06-27
➤ Subscribe Extended-release Tablets 20 mg ➤ Subscribe 2016-12-13
➤ Subscribe Tablets 100 mg, 200 mg and 400 mg ➤ Subscribe 2012-11-14
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2014-06-16
➤ Subscribe Tablets 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg ➤ Subscribe 2016-10-24
Premature patent expirations for EISAI INC

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Try a Free Trial ➤ Try a Free Trial

Non-Orange Book US Patents for Eisai Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,365,759 Intermediate compounds for preparing macrocylcic analogs ➤ Try a Free Trial
6,451,776 Water soluble prodrugs of hindered alcohols ➤ Try a Free Trial
9,102,627 Processes for preparing 3-benzazepines ➤ Try a Free Trial
7,973,160 Nitrogen-containing aromatic derivatives ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Eisai Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2001 Austria ➤ Try a Free Trial PRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
2013017,C1764361 Lithuania ➤ Try a Free Trial PRODUCT NAME: PERAMPANELUM; REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016, 2012 07 23 EU/1/12/776/017 - EU1/12/776/023 20121029
0994863/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: RUFINAMID; REGISTRATION NUMBER/DATE: SWISSMEDIC 58097 06.01.2009
00493 Netherlands ➤ Try a Free Trial PRODUCT NAME: ERIBULIN, ALSMEDE FARMACEUTISCHE ZOUTEN ERVAN, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Cantor Fitzgerald
Moodys
Cipla
Harvard Business School
Mallinckrodt
Julphar
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.